Startups
BioDuro-Sundia is a global provider of contract research, development and manufacturing outsourcing solutions. Pharmaceutical, biotechnology, and virtual companies are offered a comprehensive array of scientific services spanning the drug discovery and development continuum. Our precise balance of scientific rigor and flexibility enables fast, informed decision-making and maximizes the chances of success at every stage of any project.
From a complete understanding of project objectives at inception to timeliness on all high-quality deliverables, we work with our customers as true partners to create new efficiencies, ideas, and innovation. Our unique organizational culture is based on empowerment, respect for diversity, recognition, and cooperation. Our customers are part of the extended BioDuro-Sundia family, ensuring an exceptional customer experience and our constant pursuit of your success.
For more information about BioDuro-Sundia, please visit our website at www.bioduro-sundia.com
From a complete understanding of project objectives at inception to timeliness on all high-quality deliverables, we work with our customers as true partners to create new efficiencies, ideas, and innovation. Our unique organizational culture is based on empowerment, respect for diversity, recognition, and cooperation. Our customers are part of the extended BioDuro-Sundia family, ensuring an exceptional customer experience and our constant pursuit of your success.
For more information about BioDuro-Sundia, please visit our website at www.bioduro-sundia.com
Overview
Location
United States, California, San Diego
Employees
1001-5000
Founded date
2005
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 26, 2024 | BioDuro-Sundia's Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167 | SHANGHAI, March 26, 2024 /PRNewswire/ -- BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has been approved by Korea Food and... |
| Nov 15, 2023 | BioDuro-Sundia Radioisotope Laboratory Technology Upgrades Accelerate Innovation | SHANGHAI, Nov. 15, 2023 /PRNewswire/ -- Radioisotope assays a microanalytical method that uses radionuclides as tracers to label research objects. Compared with conventional biological sample detection techniques, Radioisotope assay has dis... |
| Apr 4, 2023 | BioDuro-Sundia Wins Life Sciences Review Top 10 BPO Award | IRVINE, Calif., April 4, 2023 /PRNewswire/ -- Life Sciences Review magazine recognizes BioDuro-Sundia as top 10 Business Process Outsourcing (BPO). BioDuro-Sundia earned this award for its high-quality service and cutting-edge technology, a... |
| Mar 28, 2023 | BioDuro-Sundia Announces Formation of Scientific Advisory Board | IRVINE, Calif., March 28, 2023 /PRNewswire/ -- BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International, announced today the establishment of a Discovery Research Scientific A... |
| Aug 11, 2022 | Advent to sell stake in manufacturer and drug developer in a deal worth over $1B — report | After almost three years of investment, private equity firm Advent International may look to sell its part in Bioduro-Sundia. A Reuters report on Monday detailed that Advent International plans to sell a majority st... |